A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients

Clinical trial NCT02614560 · TERMINATED

Trial details

NCT number: NCT02614560
Sponsor: Seagen Inc.
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia

Start date: 2015-11-01
Primary completion: 2017-02-10
Enrollment: 14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.